1. Combination Adenovirus+Pembrolizumab to Trigger Immune Virus Effects—Full Text View—ClinicalTrials.gov. Available at:
https://clinicaltrials.gov/ct2/show/NCT02798406?term=adenovirus&recrs=a&cond=Glioblastoma&rank=2
(accessed 23rd September 2017).
2. A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2—Full Text View—ClinicalTrials.gov. Available at:
https://clinicaltrials.gov/ct2/show/NCT03203421?term=adenovirus&recrs=a&cond=malaria&rank=2
(accessed 23rd September 2017).
3. Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo—Full Text View—ClinicalTrials.gov. Available at:
https://clinicaltrials.gov/ct2/show/NCT02661464?term=adenovirus&recrs=a&cond=ebola&rank=1
(accessed 23rd September 2017).
4. Lee, C. S. et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 4, 43–63 (2017).
5. Abbink, P. et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654–4663 (2007).